Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07350928 | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status | recruiting | Phase 3 | 394 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05860465 | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 2 / Phase 3 | 254 | Shanghai Pharmaceuticals Holding Co., Ltd |
| 1 |
| Jan 14, 2026 |
| clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04722978 | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 228 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07088263 | Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer | recruiting | Phase 3 | 192 | Sun Yat-sen UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06781996 | A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer(HOPE) | recruiting | Phase 3 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06144164 | A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | recruiting | Phase 3 | 285 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT07166042 | Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies(Med-RT BG) | recruiting | Phase 3 | 34 | University of UtahOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07190443 | Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)(AURA) | recruiting | Phase 3 | 290 | Japanese Foundation for Cancer ResearchOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | recruiting | Phase 3 | 400 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04254263 | Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer(ATP) | recruiting | Phase 3 | 316 | RenJi HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05744687 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | recruiting | Phase 2 / Phase 3 | 374 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07008976 | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 246 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07066280 | Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer | recruiting | Phase 3 | 326 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07057427 | Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 812 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06839001 | CRYoablation for Small Tumors As Local Treatment - SIX Trial(CRYSTAL - SIX) | recruiting | Phase 3 | 750 | Hospital do CoracaoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07003074 | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 642 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06383767 | A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | recruiting | Phase 3 | 378 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05838066 | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | recruiting | Phase 3 | 880 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT06915857 | Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position | recruiting | Phase 3 | 276 | Sunnybrook Health Sciences CentreOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06977893 | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) | recruiting | Phase 3 | 194 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04261244 | NeoRad Breast Cancer Study(NeoRad) | recruiting | Phase 3 | 1,826 | Bielefeld UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06643585 | A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse(SURVIVE HERoes) | recruiting | Phase 3 | 180 | Prof. Wolfgang JanniOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06947330 | Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy(FMASUMD66/2025) | recruiting | Phase 3 | 100 | Kholoud UsamaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06313983 | A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | recruiting | Phase 3 | 339 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer(Breast53) | recruiting | Phase 2 / Phase 3 | 45 | University of VirginiaOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06926543 | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy(CONCERT) | recruiting | Phase 3 | 858 | Dr. Tabassum WadasadawalaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT06106529 | REDucing Hot FLASHes in Women Using Endocrine Therapy.(REDFLASH) | recruiting | Phase 3 | 260 | Reinier de Graaf GroepOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06757621 | Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer | recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06304857 | CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL(PROTECTAA) | recruiting | Phase 3 | 188 | 4th Military Clinical Hospital with Polyclinic, PolandOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06711185 | Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy(DAPA-MYOCANCER) | recruiting | Phase 3 | 80 | University of Campinas, BrazilOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05440149 | The Postoperative Radiotherapy in N1 Breast Cancer Patients(PORT-N1) | recruiting | Phase 3 | 1,106 | Seoul National University HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06044623 | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients(IMPORTANT) | recruiting | Phase 3 | 495 | Region Örebro CountyOTHER | 6 | Nov 19, 2024 | clinicaltrials |
| NCT05063136 | Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer | recruiting | Phase 3 | 1,979 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | recruiting | Phase 3 | 310 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06559696 | Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 722 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2026source: clinicaltrials